RxDoctor Payments Data

Richard Mauriello, DO

Family Medicine · Berlin, NJNPI 1023012952

Payments from drug & device makers

$4,365in general payments, 2019–2025

Across 278 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$511
  • AstraZeneca$494
  • AbbVie$469
  • Otsuka America Pharmaceutical, Inc.$420
  • Johnson & Johnson$330
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$254
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,359100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,365 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$127,848
Medicare patients
221
Services billed
2,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$70,807
FarxigaDapagliflozin Propanediol102$66,817
OzempicSemaglutide50$59,512
XareltoRivaroxaban29$29,646
JardianceEmpagliflozin14$23,646
Repatha SureclickEvolocumab27$18,769
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$11,196
MyrbetriqMirabegron15$9,889
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,258
SteglatroErtugliflozin Pidolate13$4,711
Levothyroxine Sodium326$4,673
Atorvastatin Calcium277$3,380
Trazodone Hcl52$2,723
Rosuvastatin Calcium185$2,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$494$76,335117 claims
PfizerEliquis$132$70,80774 claims
Novo NordiskOzempic$239$59,51250 claims
Johnson & JohnsonXarelto$330$29,64629 claims
Boehringer IngelheimJardiance$12$23,64614 claims
Astellas Pharma US IncMyrbetriq$49$9,88915 claims
GSKTrelegy Ellipta$84$8,25814 claims
MerckSteglatro$44$4,71113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Berlin

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →